Posts

Biogen and Denali halt Parkinson’s drug in non‑genetic Parkinson’s after mid‑stage failure

on

FDA Approves Denali Therapeutics' Avlayah for Hunter Syndrome, First Treatment for Neurologic Manifestations

on

FDA Grants Accelerated Approval to Denali's Avlayah for Hunter Syndrome, Defying Rare Disease Rejection Trend

on

Eli Lilly Hires Denali Therapeutics Executive Carole Ho to Lead Neuroscience Division

on

FDA Delays Denali's Hunter Syndrome Therapy Decision by Three Months

on

Kowa Secures Expanded Rights to Nicox's Glaucoma Drug NCX 470 in Major Global Deal

on